Konstas A G, Maltezos A, Mantziris D A, Sine C S, Stewart W C
University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.
Eye (Lond). 1999 Jun;13 ( Pt 3a):314-8. doi: 10.1038/eye.1999.81.
To compare the effect of adding apraclonidine 0.5% to timolol maleate 0.5% in patients with exfoliation versus primary open-angle glaucoma. Since exfoliation glaucoma is known to demonstrate higher pressures than primary open-angle glaucoma on timolol maleate therapy alone, the authors wished to determine whether apraclonidine equalised the intraocular pressure (IOP) between these two glaucomas when added to timolol maleate.
We age-matched 30 consecutive exfoliation and 30 primary open-angle glaucoma patients who had an IOP > or = 22 mmHg on timolol maleate alone. Patients underwent IOP diurnal curve testing on timolol maleate twice daily alone and, 2 months later, following the addition of apraclonidine 0.5% three times daily. Statistical analysis of the IOP at each time point was by an unpaired t-test between groups. A paired t-test was used to evaluate the reduction in IOP from baseline within groups after the addition of apraclonidine.
On timolol maleate alone, exfoliation patients had a higher mean IOP at 06:00 and 10:00 hours as well as a higher peak, range and standard deviation of the IOP compared with primary open-angle glaucoma patients (p < 0.05). Following the addition of apraclonidine the mean, peak and range of IOP were statistically similar between groups and only the standard deviations remained higher in the exfoliation glaucoma group (p < 0.001). The mean diurnal IOP after apraclonidine was added was 20.5 +/- 7.0 mmHg in the exfoliation glaucoma group and 20.0 +/- 3.4 mmHg in the primary open-angle glaucoma group, which was not significantly different between groups (p = 0.73).
This study suggests that apraclonidine 0.5% used adjunctively with timolol maleate 0.5% solution is associated generally with similar IOP control in exfoliation and primary open-angle glaucoma patients.
比较在剥脱性青光眼与原发性开角型青光眼患者中,0.5%阿可乐定联合0.5%马来酸噻吗洛尔的效果。由于已知剥脱性青光眼在单独使用马来酸噻吗洛尔治疗时眼压高于原发性开角型青光眼,作者希望确定阿可乐定添加到马来酸噻吗洛尔中时能否使这两种青光眼的眼压达到平衡。
我们对30例连续的剥脱性青光眼患者和30例原发性开角型青光眼患者进行年龄匹配,这些患者单独使用马来酸噻吗洛尔时眼压≥22 mmHg。患者单独使用马来酸噻吗洛尔时每天进行2次眼压昼夜曲线测试,2个月后,每天3次添加0.5%阿可乐定后再次进行测试。各时间点眼压的统计分析采用组间非配对t检验。采用配对t检验评估添加阿可乐定后组内眼压较基线的降低情况。
单独使用马来酸噻吗洛尔时,与原发性开角型青光眼患者相比,剥脱性青光眼患者在06:00和10:00时平均眼压更高,眼压峰值、范围和标准差也更高(p < 0.05)。添加阿可乐定后,两组间眼压的平均值、峰值和范围在统计学上相似,仅剥脱性青光眼组的标准差仍较高(p < 0.001)。添加阿可乐定后,剥脱性青光眼组的平均昼夜眼压为20.5±7.0 mmHg,原发性开角型青光眼组为20.0±3.4 mmHg,两组间无显著差异(p = 0.73)。
本研究表明,0.5%阿可乐定与0.5%马来酸噻吗洛尔溶液联合使用时,在剥脱性青光眼和原发性开角型青光眼患者中通常能实现相似的眼压控制。